SCHEMBL8005199

SCHEMBL8005199

Cc1cc2c(cc1C)OCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.44
ABCG2 Q9UNQ0 1/20 0.43
ATM Q13315 1/20 0.41
ALOX5 P09917 1/20 0.41
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
HBB P68871 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPK9 P45984 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
CHRNA7 P36544 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1027495 0.82 MEN1 (0.47) CYP3A4ALOX5ALDH1A1HSD17B10TDP1
SCHEMBL4146714 0.82 CYP3A4 (0.37) CYP3A4ABCG2ATMALOX5ALDH1A1
SCHEMBL30030734 0.82 MEN1 (0.47) CYP3A4ALOX5ALDH1A1HSD17B10TDP1
SCHEMBL18103322 0.82 CYP3A4 (0.37) CYP3A4ABCG2ATMALOX5ALDH1A1
SCHEMBL8259845 0.82 NPC1 (0.46) CYP3A4ABCG2ATMALOX5ALDH1A1
SCHEMBL9908794 0.82 CYP3A4 (0.46) CYP3A4ATMALOX5ALDH1A1HSD17B10
SCHEMBL2022289 0.82 CD44 (0.46) CYP3A4ALOX5ALDH1A1KDM4EMAPT
SCHEMBL4594563 0.82 ALDH1A1 (0.42) CYP3A4ALOX5ALDH1A1MAPTMEN1
SCHEMBL8525889 0.81 ALDH1A1 (0.47) ATMALDH1A1HSD17B10KDM4EMAPT
SCHEMBL13754300 0.80 ACHE (0.41) CYP3A4ALDH1A1HSD17B10TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024115641-A1 NONCOVALENT KEAP1-NRF2 SMALL-MOLECULE INHIBITORS UNIVERSITY OF COPENHAGEN (DK) 2024-06-06 WO disclosed
WO-2023249473-A1 ANTIBODY-DRUG CONJUGATE WITH TWO TYPES OF DRUG-LINKER CONJUGATES ON SINGLE ANTIBODY 주식회사 피노바이오 2023-12-28 WO disclosed
WO-2023214849-A1 CONJUGATE OF DDX5 PROTEIN-BINDING CAMPTOTHECIN-BASED DRUG LINKED TO ACID-SENSITIVE LINKER AND IMMUNOCONJUGATE USING SAME 주식회사 피노바이오 2023-11-09 WO disclosed
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN-LA ROCHE INC. (US) 2023-10-19 US disclosed
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS VANDERBILT UNIVERSITY 2023-09-28 US disclosed
US-11691980-B2 Liphagal analog and multi-targeted kinase inhibitor containing liphagal or analog thereof TOHOKU UNIVERSITY (JP) 2023-07-04 US disclosed
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2023-06-29 US disclosed
EP-2694505-B1 HSP90 INHIBITORS SLOAN KETTERING INST CANCER RES (US) 2022-04-27 EP disclosed
US-20220024944-A1 COMPOUNDS TARGETING MUTANT CALRETICULIN MYELOPRO DIAGNOSTICS AND RESEARCH GMBH (AT) 2022-01-27 US disclosed
WO-2022006228-A1 ISOQUINOLINE DERIVATIVES, METHODS OF SYNTHESIS AND USES THEREOF PROSETTA BIOSCIENCES, INC. (US) 2022-01-06 WO disclosed
US-7259229-B2 Electroactive fluorene polymers having perfluoralkyl groups, process for preparing such polymers and devices made with such polymers E.I. DU PONT DE NEMOURS AND COMPANY (US) 2007-08-21 US disclosed
US-7230070-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-06-12 US disclosed
US-7220820-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-22 US disclosed
US-7214763-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-08 US disclosed
US-7211643-B2 Electroactive fluorene copolymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-01 US disclosed
US-7183365-B2 Electroactive fluorene polymers having perfluoroalkyl groups, process for preparing such polymers and devices made with such polymers E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-27 US disclosed
US-7183366-B2 Aromatic copolymers from dihalofluorene compounds and another dihalo- or diborono- aromatic monomers; organic electroluminescent polymers for use in light-emitting diodes E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-02-27 US disclosed
WO-2004089925-A1 PI-3 KINASE INHIBITOR PRODRUGS SEMAFORE PHARMACEUTICALS, INC. (US) 2004-10-21 WO disclosed
US-4058607-A DIHALOVINYL DIALKYL PHOSPHATE, 1,3-BENZODIOXOLES AIRWICK INDUSTRIES, INC. (US) 1977-11-15 US disclosed
US-3962415-A Insecticide evaporator comprising DDVP with synergized benzodioxole compound as stabilizer AIRWICK INDUSTRIES, INC. (US) 1976-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203048-A1 SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS ACE, ACE2, PKD1 CYP3A4 221/4885ABCG2 1247/4885ATM 3836/4885
US-20230331715-A1 SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HAVCR2, NR1I3, NR1H4 CYP3A4 62/4885ABCG2 1045/4885ATM 4000/4885
US-11691980-B2 Liphagal analog and multi-targeted kinase inhibitor containing liphagal or analog thereof STK16, STK3, STK4 CYP3A4 4614/4885ABCG2 4496/4885ATM 134/4885
US-20230303552-A1 ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS CHRM5, CHRM1, CHRM2 CYP3A4 641/4885ABCG2 204/4885ATM 1324/4885
US-20220024944-A1 COMPOUNDS TARGETING MUTANT CALRETICULIN CALR, MCL1, CALD1 CYP3A4 4829/4885ABCG2 1572/4885ATM 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.